Limited coverage criteria – cyproterone
Last updated on March 17, 2025
Return to Special Authority drug list
Generic name |
cyproterone |
Strength & form |
100 mg/1 mL ampoule 50 mg tablet |
Special Authority criteria |
Approval period |
|---|---|
|
Indication of need to reduce aggressive sexual drive |
Indefinite |
Practitioner exemptions
- None
Special notes
- Criteria applicable for all plans, including Plan G
- For any cancer-related condition, please contact the British Columbia Cancer Agency at 604-877-6098 ext. 4610